Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue: 2016-2019

Historic Current Deferred Revenue for Ultragenyx Pharmaceutical (RARE) over the last 2 years, with Mar 2019 value amounting to $69,000.

  • Ultragenyx Pharmaceutical's Current Deferred Revenue fell 90.46% to $69,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $69,000, marking a year-over-year decrease of 90.46%. This contributed to the annual value of $6.0 million for FY2017, which is 1655.43% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Current Deferred Revenue of $69,000 as of Q1 2019, which was down 94.45% from $1.2 million recorded in Q2 2018.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Current Deferred Revenue peaked at $6.0 million during Q4 2017, and registered a low of $69,000 during Q1 2019.
  • Moreover, its 3-year median value for Current Deferred Revenue was $695,000 (2017), whereas its average is $1.4 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Current Deferred Revenue surged by 1,655.43% in 2017, and later tumbled by 90.46% in 2019.
  • Quarterly analysis of 4 years shows Ultragenyx Pharmaceutical's Current Deferred Revenue stood at $341,000 in 2016, then surged by 1,655.43% to $6.0 million in 2017, then skyrocketed by 85.95% to $1.2 million in 2018, then tumbled by 90.46% to $69,000 in 2019.
  • Its Current Deferred Revenue stands at $69,000 for Q1 2019, versus $1.2 million for Q2 2018 and $723,000 for Q1 2018.